Statistics from Altmetric.com
The prediction of treatment outcome of patients with rheumatoid arthritis (RA) may avoid wasting time and cost of treatment, and allow better targeting of aggressive treatment. Recently, an amino acid-changing polymorphism in the gene encoding the Fcγ IIIA receptor (FcγRIIIA), valine (V)/phenylalanine (F) (rs396991), was found to be associated with increased likelihood of response to tumour necrosis factor (TNF)-α inhibitors in the treatment of RA.1 The aim of the present study was to determine whether this FcγRIIIA V/F polymorphism is associated with treatment outcome of infliximab (the first TNF-α inhibitor approved in Japan) in Japanese patients with RA.
The study was approved by the Tokyo Women’s Medical University Genome Ethics Committee. The …
Competing interests: None.
Funding: Supported by grants provided by the Japan Orthopaedics and Traumatology Foundation (KI), Takeda Science Foundation (KI), and the Japanese Ministry of Education, Culture, Sports, Science and Technology (KI, ST)
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.